DISCOUNT-ZERTIFIKAT - BRISTOL-MYERS SQUIBB

DISCOUNT-ZERTIFIKAT - BRISTOL-MYERS SQUIBB Stock

DE000HC8RED1

Real-time BOERSE MUENCHEN 05:45:27 2024-06-03 EDT
36.76 ^EUR	+0.66%

1 month	-8.40%
3 months	-16.14%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart DISCOUNT-ZERTIFIKAT - BRISTOL-MYERS SQUIBB

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	06-02	RE
GSK blood cancer drug nearly halves risk of death in late-stage trial	06-02	RE
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer	06-01	BU
Bristol Myers Squibb Announces Results from the Phase 3 KRYSTAL-12 Study Evaluating KRAZATI®?	06-01	CI

More news

Quotes 5-day view

Date	Price	Change
24-06-03	36.76	+0.66%
24-05-31	36.52	+1.36%
24-05-30	36.03	-0.50%
24-05-29	36.21	+0.53%
24-05-28	36.02	-2.73%

Real-time BOERSE MUENCHEN

Last update June 03, 2024 at 05:45 am

More quotes

Static data

Product type	Certificats Discount
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	UniCredit
WKN	HC8RED
ISIN	DE000HC8RED1
Date issued	2023-08-16
Cap	56 $
Last trading day	2024-12-20
Maturity	2024-12-20 (201 Days)
Parity	1 : 1
Emission price	45.44 €
Emission volume	N/A
Payment day	2024-12-31
Bonus	- €
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Discount (ask)	2.850 %
Sideways yield	3.004 %
Sideways yield pa	5.482 %
Outperformance point	57.64 $
Break even	39.93 €
Highest since issue	46.34 €
Lowest since issue	35.82 €
Spread	0.05 €
Spread %	0.14%
Distance Cap	-14.88 $
Distance Cap %	-36.17%
Max. earning	14.83
Max. earning %	40.26 %

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.09 USD

Average target price

53.19 USD

Spread / Average Target

+29.46%

Consensus